156 related articles for article (PubMed ID: 2573055)
21. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters.
Szepeshazi K; Schally AV; Cai RZ; Radulovic S; Milovanovic S; Szoke B
Cancer Res; 1991 Nov; 51(21):5980-6. PubMed ID: 1682039
[TBL] [Abstract][Full Text] [Related]
22. Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors.
Lee MT; Liebow C; Kamer AR; Schally AV
Proc Natl Acad Sci U S A; 1991 Mar; 88(5):1656-60. PubMed ID: 1672042
[TBL] [Abstract][Full Text] [Related]
23. Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix.
Halmos G; Schally AV; Kahan Z
Int J Oncol; 2000 Aug; 17(2):367-73. PubMed ID: 10891548
[TBL] [Abstract][Full Text] [Related]
24. Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice.
Lamharzi N; Halmos G; Jungwirth A; Schally AV
Int J Oncol; 1998 Sep; 13(3):429-35. PubMed ID: 9683774
[TBL] [Abstract][Full Text] [Related]
25. Antitumor effects of analogs of LH-RH and somatostatin: experimental and clinical studies.
Schally AV; Srkalovic G; Szende B; Redding TW; Janaky T; Juhasz A; Korkut E; Cai RZ; Szepeshazi K; Radulovic S
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1061-7. PubMed ID: 1981009
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones.
Redding TW; Schally AV
Proc Natl Acad Sci U S A; 1984 Jan; 81(1):248-52. PubMed ID: 6141560
[TBL] [Abstract][Full Text] [Related]
27. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination.
Szepeshazi K; Milovanovic S; Lapis K; Groot K; Schally AV
Breast Cancer Res Treat; 1992; 21(3):181-92. PubMed ID: 1355375
[TBL] [Abstract][Full Text] [Related]
28. Regulation of luteinizing hormone-releasing hormone receptor binding by heterologous and autologous receptor-stimulated tyrosine phosphorylation.
Liebow C; Lee MT; Kamer AR; Schally AV
Proc Natl Acad Sci U S A; 1991 Mar; 88(6):2244-8. PubMed ID: 1672452
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of binding of cytotoxic analogs of luteinizing hormone-releasing hormone to human breast cancer and mouse MXT mammary tumor.
Milovanovic SR; Radulovic S; Schally AV
Breast Cancer Res Treat; 1992; 24(2):147-58. PubMed ID: 8443402
[TBL] [Abstract][Full Text] [Related]
30. Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
Pinski J; Reile H; Halmos G; Groot K; Schally AV
Int J Cancer; 1994 Oct; 59(1):51-5. PubMed ID: 7927904
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone.
Yano T; Pinski J; Radulovic S; Schally AV
Proc Natl Acad Sci U S A; 1994 Mar; 91(5):1701-5. PubMed ID: 8127868
[TBL] [Abstract][Full Text] [Related]
32. Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model.
Schally AV; Kook AI; Monje E; Redding TW; Paz-Bouza JI
Proc Natl Acad Sci U S A; 1986 Nov; 83(22):8764-8. PubMed ID: 2946045
[TBL] [Abstract][Full Text] [Related]
33. Alterations in receptor-mediated kinases and phosphatases during carcinogenesis.
Crean DH; Liebow C; Lee MT; Kamer AR; Schally AV; Mang TS
J Cancer Res Clin Oncol; 1995; 121(3):141-9. PubMed ID: 7713985
[TBL] [Abstract][Full Text] [Related]
34. Effect of treatment with LHRH analogs containing cytotoxic radicals on the binding characteristics of receptors for luteinizing-hormone-releasing hormone in MXT mouse mammary carcinoma.
Milovanovic SR; Monje E; Szepeshazi K; Radulovic S; Schally A
J Cancer Res Clin Oncol; 1993; 119(5):273-8. PubMed ID: 8382705
[TBL] [Abstract][Full Text] [Related]
35. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
Redding TW; Schally AV; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs JT
Cancer Res; 1992 May; 52(9):2538-44. PubMed ID: 1568223
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.
Yano T; Pinski J; Halmos G; Szepeshazi K; Groot K; Schally AV
Proc Natl Acad Sci U S A; 1994 Jul; 91(15):7090-4. PubMed ID: 7518926
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of transforming growth factor-alpha and epidermal growth factor receptor, but not epidermal growth factor, in exocrine pancreatic tumours in hamsters.
Visser CJ; Bruggink AH; Korc M; Kobrin MS; de Weger RA; Seifert-Bock I; van Blokland WT; van Garderen-Hoetmer A; Woutersen RA
Carcinogenesis; 1996 Apr; 17(4):779-85. PubMed ID: 8625491
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH.
Yano T; Korkut E; Pinski J; Szepeshazi K; Milovanovic S; Groot K; Clarke R; Comaru-Schally AM; Schally AV
Breast Cancer Res Treat; 1992; 21(1):35-45. PubMed ID: 1391973
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and biological activity of [D-Trp6] chicken luteinizing hormone-releasing hormone.
Millar RP; King JA
Peptides; 1983; 4(4):425-9. PubMed ID: 6316292
[TBL] [Abstract][Full Text] [Related]
40. Effect of bombesin, gastrin-releasing peptide (GRP)(14-27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters.
Szepeshazi K; Schally AV; Groot K; Halmos G
Int J Cancer; 1993 May; 54(2):282-9. PubMed ID: 8387464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
